whats retatrutide What is Retatrutide? Exploring The New Multi-Action Weight Loss Treatment In Development – Cured Pharmacy Retatrutide: The New Triple-Agonist Weight

The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy

Our guides on Anthem GLP-1 coverage and Blue Cross Blue Shield coverage detail what specific plans offer

By addressing both blood sugar control and weight management, retatrutide offers a comprehensive approach to diabetes management

Important Note: Retatrutide is currently an investigational drug and not yet FDA-approved for general clinical use